Result: Risk Minimisation Materials for medicines starting with the letter L

Lariam

Neon Healthcare Ltd

Checklist for Healthcare Professionals

Checklist for the prescription, supply or recommendation of Lariam® (mefloquine) for malaria chemoprophylaxis

For Healthcare Professionals

Guide for Healthcare Professionals

This guide is intended to provide you with information regarding side effects which may be associated with chemoprophylactic use of Lariam® (mefloquine).

For Healthcare Professionals

Patient Alert Card

Lariam Patient Alert Card

Leflunomide

Sandoz Limited

Leflunomide 10 mg and 20 mg Film-coated Tablets: Specific safety information for Phsyicians

This educational material is intended to minimize several risks identified in the frame of the European risk management plan established for Leflunomide. The most important risks you should be aware of when prescribing Leflunomide include: • Risk of hepatotoxicity, including very rare cases of severe liver injury, which may be fatal. • Risk of hematotoxicity, including rare cases of pancytopenia, leucopenia, eosinophilia and very rare cases of agranulocytosis. • Risks of infections including rare cases of severe uncontrolled infections (sepsis), which may be fatal. • Risk of serious birth defects when administered during pregnancy. Counselling of patients, careful monitoring and following recommendations regarding the wash-out procedure are required to minimise these risks. Complete prescribing information is provided in the approved Summary of Product Characteristics (SmPC) for Leflunomide.

For Healthcare Professionals

medac GmbH

Leflunomide medac - RMP Patient Leaflet

Risk Management Educational Material

Leflunomide medac - RMP Physician Leaflet

In addition to the Summary of Product Characteristics, this leaflet was developed by the marketing authorisation holder to inform you about all delicate issues potentially arising from Leflunomide medac therapy. Counselling patients on important risks associated with Leflunomide medac therapy and appropriate precautions when using the medicine is required.

For Healthcare Professionals

Mylan

Leflunomide Physician Leaflet

This leaflet is to highlight the most important risks associated with Leflunomide and to emphasize the need for counselling patients about those important risks

For Healthcare Professionals

Tillomed Laboratories Ltd

Leflunomide Tillomed 10mg & 20mg Tablets - Prescriber's Guide

Prescriber's Guide

For Healthcare Professionals

Lemtrada

Sanofi Genzyme

Lemtrada (alemtuzumab) - Healthcare Professional (HCP) Guide - Risk Minimisation Information for Healthcare Professionals

This guide has been developed for prescribers and healthcare professionals (HCPs) involved in the care of patients treated with Lemtrada (alemtuzumab), to provide further information about the potential serious risks associated with the use of this medicine. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For Healthcare Professionals

Lemtrada (alemtuzumab) - Patient Alert Card - Risk Minimisation Information for Patients

The card should be provided to patients prior to treatment by the prescribing physician and is designed to alert other HCPs that the patient has been prescribed Lemtrada (alemtuzumab) and includes details on the associated risks of treatment and contact details of the prescriber. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Lemtrada (alemtuzumab) - Patient Guide - Risk Minimisation Information for Patients

The guide should be provided to patients prior to treatment by the prescribing physician and includes a description of the risks of treatment, guidance on what to do in the event of risks occurring including your doctors contact details and an overview of treatment monitoring. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Lemtrada (alemtuzumab) – Prescriber check list - Risk Minimisation Information for Healthcare Professionals

Describes required initial screening tests, pre-treatment vaccination course, premedication, general health, and pregnancy and contraception checks immediately before treatment and the subsequent monitoring activities. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For Healthcare Professionals

Lenalidomide

Teva UK Limited

Combined HCP Lenalidomide RMM

Combined Lenalidomide RMM for HCPs only containing the following: 1) HCP Brochure 2) HCP Treatment Checklist 3) HCP Registration & Dispensing of Lenalidomide 4) HCP Frequently Asked Questions (FAQs)

For Healthcare Professionals

Combined Patient Lenalidomide RMM

Combined Lenalidomide RMM for Patients only containing the following: 1) Lenalidomide Patient Pocket Card 2) Lenalidomide Patient Brochure

Accord Healthcare Limited

Lenalidomide Adverse Event Form

The safe use of this product is essential. Adverse events or any cases of suspected/confirmed pregnancy or foetal exposure should always be reported to Accord. Any adverse events can also be reported direct to the MHRA via the Yellow card scheme website: www.mhra.gov.uk/yellowcard or search for the MHRA Yellow Card in the Google Play or Apple App Store.

For Healthcare Professionals

Lenalidomide Healthcare Professional pack

This material contains the information needed by the healthcare professionals for prescribing and dispensing Lenalidomide, including information about the Pregnancy Prevention Programme (PPP). It is a requirement that the healthcare professional ensures they read and understand the PPP prior to prescribing and dispensing lenalidomide to ANY patient. Please also refer to the Summary of Product Characteristics (SmPC) for lenalidomide.

For Healthcare Professionals

Lenalidomide Information for Healthcare Professionals

This material contains the information needed by the healthcare professionals for prescribing and dispensing Lenalidomide, including information about the Pregnancy Prevention Programme (PPP). It is a requirement that the healthcare professional ensures they read and understand the PPP prior to prescribing and dispensing lenalidomide to ANY patient. Please also refer to the Summary of Product Characteristics (SmPC) for lenalidomide.

Lenalidomide Information for the Patients

This material should be given to each patient receiving treatment with lenalidomide as it provides important details about the Pregnancy Prevention Programme, including what the patient needs to be aware of before, during and after taking lenalidomide along with how to report any side effects.

Lenalidomide Male Treatment Initiation Form

This Treatment Initiation Form must be completed for each male patient prior to the initiation of their Lenalidomide treatment. It is mandatory that all males receive counselling and education to be made aware of the risks of lenalidomide. The aim is to protect the patient and any possible foetuses by ensuring the patient is fully informed of and understands the risk of teratogenicity and other adverse effects associated with the use of lenalidomide.

Lenalidomide Patient Information Card

The patient card must be given to patients receiving treatment with lenalidomide, as it provides important details about the Pregnancy Prevention Programme, including what they need to be aware of before, during and after taking lenalidomide and how to report side effects.

Lenalidomide Pharmacy Registration Form

The Pharmacy registration form must be completed by the chief Pharmacist or their appointed deputy to be able to order and dispense lenalidomide. Pharmacies will only be able to dispense lenalidomide if they are registered with Accord.

For Healthcare Professionals

Lenalidomide Pregnancy Form

The safe use of this product is essential. Any cases of suspected pregnancy or confirmed pregnancy should be IMMEDIATELY reported to Accord. Any adverse events can also be reported direct to the MHRA via the Yellow card scheme website: www.mhra.gov.uk/yellowcard or search for the MHRA Yellow Card in the Google Play or Apple App Store.

Lenalidomide Pregnancy Outcome Form

The safe use of this product is essential. Any cases of suspected pregnancy or confirmed pregnancy should be IMMEDIATELY reported to Accord. Any adverse events can also be reported direct to the MHRA via the Yellow card scheme website: www.mhra.gov.uk/yellowcard or search for the MHRA Yellow Card in the Google Play or Apple App Store.

Lenalidomide Prescription Authorisation Form

Each prescription of Lenalidomide must be accompanied by a newly completed Prescription Authorisation Form to confirm the patient has been counselled about the teratogenic risk of lenalidomide and the requirement for the use of contraception and the continuous use of an effective contraception whilst taking lenalidomide. Also, for woman of childbearing potential the confirmation of having a negative pregnancy test every 4-weeks, before each prescription to ensure they are not pregnant. Completion of this information is mandatory for ALL patients.

Lenalidomide Treatment Checklist and Algorithm

The lenalidomide checklist is to assist the healthcare professional with counselling a patient before they commence lenalidomide treatment to ensure it is used safety and correctly. The Algorithm provides high level steps for the process of Pharmacy registration and dispensing of lenalidomide.

Lenalidomide Women of Childbearing Potential Treatment Initiation Form

This Treatment Initiation Form must be completed for each woman of childbearing potential prior to the initiation of their lenalidomide treatment. It is mandatory that women of childbearing potential receive counselling and education to be made aware of the risks of Lenalidomide. Lenalidomide is contraindicated in women of childbearing potential unless all terms of counselling are met. The aim of the Treatment Initiation Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with lenalidomide.

Lenalidomide Women of Non-Childbearing Potential Treatment Initiation Form

This Treatment Initiation Form must be completed for each woman of non-childbearing potential prior to the initiation of their Lenalidomide treatment. It is mandatory that women of non-childbearing potential receive counselling and education to be made aware of the risks of lenalidomide. The aim of the Treatment Initiation Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with lenalidomide.

Levest

Morningside Healthcare Ltd

Checklist for Prescribers - Levest

Please use this checklist in conjunction with the SPC during combined hormonal contraceptives consultations. Risk of Thromboembolism.

For Healthcare Professionals

Important Information for Women - Levest Tablets

This is a bit more information about the recommendations of combined hormonal contraceptives, in particular the risk of blood clots. Includes key points to bear in mind.

Patient Card - Levest

Important information for women about the risk of blood clots with the combined hormonal contraceptives.

Levetiracetam

Aurobindo Pharma - Milpharm Ltd.

Levetiracetam oral solution - Risk of medication errors associated with overdose

Levetiracetam overdose can lead to serious adverse event. With every prescription, physicians and pharmacists should advise the patient and/or caregiver on how to measure the prescribed dose

For Healthcare Professionals

Levobunolol

Aspire Pharma Ltd

Dispensing guide

An aide-mémoire for pharmacists dispensing Librachrom to ensure the unique features of the product are explained to patients.

Levonelle

Bayer plc

Levonelle One Step Patient Questionnaire Checklist

Instructions for Pharmacists supplying Levonelle One Step 1500 microgram tablet as emergency contraception

For Healthcare Professionals

Levonorgestrel Patient Sheet

Levonorgestrel emergency contraception: important information for women taking other medicines

Levonorgestrel

Lupin Healthcare (UK) Ltd

Advice for women taking Levonorgestrel tablets

Advice for women taking Levonorgestrel tablets Levonorgestrel 1.5mg Tabletsl PL35507-0126

Checklist for Pharmacists

Checklist for Pharmacists Levonorgestrel 1.5mg Tablets PL 35507-0126

Levonorgestrel Patient Sheet

Levonorgestrel emergency contraception: important information for women taking other medicines. Some medicines or herbal remedies that contain the ingredient St. John's wort, might reduce how well levonorgestrel emergency contraception works. Tell the doctor, pharmacist or nurse if you are currently taking a medicine to treat any of the following, or if you have used one in the past 4 weeks: epilepsy, tuberculosis, HIV, a fungal infection, or if you have taken any herbal remedies that contain the ingredient St. John's wort.

Mylan

Educational material for Pharmacists & Patients

Checklist for Pharmacists and Patients

THE BOOTS COMPANY PLC

Levonorgestrel Patient Sheet

Levonogestrel emergency contraception: important information for women taking other medicines.

Gedeon Richter (UK) Ltd

Levonorgestrel Patient Sheet

Levonorgestrel emergency contraception: important information for women taking other medicines.

Postinor 1500mcg Patient Questionnaire checklist

Instructions for Pharmacists supplying Postinor 1500 microgram tablet as emergency contraception

For Healthcare Professionals

Levosert

Gedeon Richter (UK) Ltd

Levosert HCP Educational Brochure

This educational brochure is intended to minimise the risk of application errors due to confusion of different types of IUS and to reduce the risk of ectopic pregnancies.

For Healthcare Professionals

Levosert Patient Card

Levosert Patient Card

For Healthcare Professionals

Liberize

Teva UK Limited

Essential information for the supply of Liberize

UK Essential information for the supply of Liberize (sildenafil)

For Healthcare Professionals

Essential information for the supply of Liberize (sildenafil)

Essential information for the supply of Liberize (sildenafil) - UK

For Healthcare Professionals

Liberize (sildenafil) Pharmacy Checklist

Liberize (sildenafil) Pharmacy Checklist - UK

For Healthcare Professionals

Liberize Pharmacy Checklist

UK Liberize (sildenafil) Pharmacy Checklist

For Healthcare Professionals

Libtayo

SANOFI

Libtayo-Patient Alert Card- Patients treated with cemiplimab

This Patient Alert Card will help you identify and report any symptoms of side effects from your treatment with cemiplimab. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Libtayo-Patient Guide- Patients treated with cemiplimab

This Patient Guide will help you identify and report any symptoms of side effects from your treatment with cemiplimab. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Lixiana

Daiichi Sankyo UK Limited

Lixiana (edoxaban) Patient Alert Card

Every patient prescribed Lixiana will receive a Patient Alert Card in the medication pack. This will inform doctors, dentists, pharmacists and other healthcare professionals about the patient’s anticoagulation treatment, along with emergency contact details. Encourage patients to have this card with them at all times and to show it to healthcare professionals prior to any consultation or procedure. Patients should be reminded of the importance of compliance to their treatment regimen, the need to watch for signs and symptoms of bleeding and when to seek medical advice. Patient Alert Cards are available from [email protected] or by calling 08000285122.

Lixiana (edoxaban) Prescriber Guide

This risk minimisation material has been developed for Lixiana for all indications. Please ensure that you are familiar with this material as it contains important safety information. In particular, it is aimed at increasing awareness about the potential risk of bleeding during treatment with Lixiana and providing guidance on how to manage that risk.

For Healthcare Professionals

Lizinna

Morningside Healthcare Ltd

Checklist for Prescribers - Lizinna

Please use this checklist in conjunction with the SPC during combined hormonal contraceptives consultations. Risk of thromboembolism.

For Healthcare Professionals

Important Information for Women - Lizinna

This is more information on recommendations of safety of combined hormonal contraceptives, in particular the risk of blood clots.

Patient Card - Lizinna

Important Information for women about risk of blood clots with combined hormonal contraceptives.

Logynon

Bayer plc

CHCs - Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers

For Healthcare Professionals

CHCs - Q&A on Important Info for Women

Combined hormonal contraceptives: Q&As about the important information for women.

CHCs - Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

Logynon ED

Bayer plc

CHCs - Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers

For Healthcare Professionals

CHCs - Q&A on Important Info for Women

Combined hormonal contraceptives: Q&As about the important information for women.

CHCs - Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

Lojuxta

Amryt Pharmaceuticals DAC

Lojuxta (lomitapide) Healthcare Professional Guide

Healthcare professional guide contains information on the serious risks associated with Lojuxta and how to help mitigate these risks.

For Healthcare Professionals

Lojuxta Alert Card

The purpose of the patient alert card is to inform health care professionals of potential drug-drug interactions before any additional medicinal product is taken. Patients will be instructed to carry this card and show it to all doctors and pharmacists involved in their treatment.

Lojuxta Patient Care Guide

Patient care guide containing important safety information for patients treated with Lojuxta (lomitapide).

Losartan+Hydrochlorothiazide

Mylan

Direct HCP Communication: Hydrochlorothiazide, risk of non‐melanoma skin cancer

Direct Healthcare Professional Communication Hydrochlorothiazide: Risk of non‐melanoma skin cancer

For Healthcare Professionals

Aurobindo Pharma - Milpharm Ltd.

Losartan/HCTZ- HCP letter- Hydrochlorothiazide and the risk of non-melanoma skin cancer

The prescriber should inform the patients taking hydrochlorothiazide (HCTZ) containing medicines of the risk of non-melanoma skin cancer. Patients should be advised to limit the exposure to sunlight and UV rays and use adequate protection when exposed to sunlight and UV rays to minimise the risk of skin cancer

For Healthcare Professionals

Lovima

Maxwellia Limited

Healthcare Professional Training

To support the Healthcare Professional in conducting effective, patient-specific, clinical consultations on contraception, and enable them to appropriately supply Lovima® 75 microgram film-coated tablets (desogestrel).

For Healthcare Professionals

Optional Pharmacist Checklist

• Use of this checklist is optional and this consultation checklist is provided to act as a reminder for pharmacists. • It covers the key considerations when determining suitability of Lovima 75 microgram film-coated tablets for women who request them and advice to provide when supply is made.

For Healthcare Professionals

Lucentis

Novartis Pharmaceuticals UK Ltd

Lucentis (ranibizumab) - Patient information booklet (AMD) - for patients

A booklet containing important safety information for patients treated with Lucentis (ranibizumab) in wet (neovascular) age related macular degeneration (nAMD). An audio version is available on eMC.

Lucentis (ranibizumab) - Patient information booklet (CNV) - for patients

A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with visual impairment due to choroidal neovascularisation (CNV)secondary to pathological myopia. An audio version is available on eMC.

Lucentis (ranibizumab) - Patient information booklet (DMO/PDR) - for patients

A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with proliferative diabetic retinopathy (PDR) and/or visual impairment due to diabetic macular oedema (DMO). An audio version is available on eMC.

Lucentis (ranibizumab) - Patient information booklet (RVO) - for patients

A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with visual impairment due to retinal vein occlusion (RVO). An audio version is available on eMC.

Lutigest

Advanced Accelerator Applications

Lutathera Patient Guide

Patient guide for Lutathera treatment procedure

Luxturna

Novartis Pharmaceuticals UK Ltd

Luxturna (voretigene neparvovec) - Patient Alert card - for Patients

Patient card to track treatment and provide useful contact details

Luxturna (voretigene neparvovec) - Pharmacy training material - for Healthcare Professionals

Pharmacy manual for dose preparation of Luxturna

For Healthcare Professionals

Luxturna (voretigene neparvovec) - Surgical training material - for Healthcare Professionals

Surgical manual for the administration of Luxturna

For Healthcare Professionals

Lynparza

AstraZeneca UK Limited

Lynparza Dear Healthcare Professional Communication

To reduce the risk of medication errors with the new tablet pharmaceutical form.

For Healthcare Professionals

Lynparza Dear Healthcare Professional Communication

Lynparza Dear Healthcare Professional Communication

For Healthcare Professionals